Prof. Dr. Anette-Gabriele Ziegler
Academic Career and Research Areas
The research of Professor Ziegler (b. 1958) focuses primarily on the understanding of the natural history of type 1 diabetes in humans, the identification of the mechanisms and predictive markers of the disease and the translation of findings into trials to prevent type 1 diabetes. Another major focus area is the elucidation of the impact of gestational diabetes and maternal hyperglycemia on the long term risk of obesity and type 2 diabetes in mothers and their offspring.
Professor Ziegler studied medicine at LMU Munich. After obtaining her license to practice medicine and receiving her doctorate from LMU, she worked as a research fellow at the Joslin Diabetes Center in Boston, USA (1987-89). She was awarded the prestigious Heisenberg Career Development Award of the German Research Foundation (DFG) (1993), acquired her German medical board certification in internal medicine (1991) and endocrinology (1994) and subsequently became adjunct professor at LMU Munich (1998). From 2007 to 2009 she was Director of the Department of Endocrinology at Klinikum Schwabing in Munich. At the beginning of 2010, she was appointed to the Chair of Diabetes and Gestational Diabetes at the TUM university hospital, Klinikum rechts der Isar, and became Director of the newly founded Institute for Diabetes Research at the Helmholtz Zentrum München. She has been President of the Immunology of Diabetes Society since 2017. Since 2015, she has been leading the international study platform GPPAD (Global Platform for the Prevention of Autoimmune Diabetes).
- George Eisenbarth Award for Type 1 Diabetes Prevention of the JDRF (2018)
- Werner Creutzfeldt Award of the German Diabetes Society (2018)
- Brownlee Lecture Award, Joslin Diabetes Center, Boston, USA (2014)
- Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award, Juvenile Diabetes Research Foundation (2013)
- Heisenberg Career Development Award of the German Research Foundation (DFG) (1993)
Key Publications (all publications)
Ziegler AG, Kick K, Bonifacio E, Haupt F, Hippich M, Dunstheimer D, Lang M, Laub O, Warncke K, Lange K, Assfalg R, Jolink M, Winkler C, Achenbach P for the Fr1da Study Group: “Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany”. JAMA. 2020; 323(4):339-351.Abstract
Vehik K, Lynch KF, Wong MC, Tian X, Ross MC, Gibbs RA, Ajami NJ, Petrosino JF, Rewers M, Toppari J, Ziegler AG, She JX, Lernmark A, Akolkar B, Hagopian WA, Schatz DA, Krischer JP, Hyöty H, Lloyd RE; TEDDY Study Group: “Prospective virome analyses in young children at increased genetic risk for type 1 diabetes”. Nat Med. 2019; 25(12):1865-1872.Abstract
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group: “An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes”. N Engl J Med. 2019; 381(7):603-613.Abstract
Bonifacio E, Beyerlein A, Hippich M, Winkler C, Vehik K, Weedon MN, Laimighofer M, Hattersley AT, Krumsiek J, Frohnert BI, Steck AK, Hagopian WA, Krischer JP, Lernmark Å, Rewers MJ, She JX, Toppari J, Akolkar B, Oram RA, Rich SS, Ziegler AG; TEDDY Study Group: "Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: A prospective study in children". PLoS Medicine. 2018; 15(4): e1002548.Abstract
Beyerlein A, Donnachie E, Jergens S, Ziegler AG: "Infections in Early Life and Development of Type 1 Diabetes". JAMA. 2016; 315(17): 1899-901.Abstract